Vertex tests shorter Incivek therapy in patient subset

Vertex Pharmaceuticals ($VRTX) will put its Incivek hepatitis C treatment through a trial to determine whether combination therapy for the disease could be shortened to 12 weeks in patients with a particular genetic variation associated with a stronger and faster response to antiviral therapy. Vertex release

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.